1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. PharmaSGP Holding SE
  6. Summary
    PSG   DE000A2P4LJ5

PHARMASGP HOLDING SE

(PSG)
  Report
Delayed Xetra  -  05/23 11:36:08 am EDT
25.00 EUR   +2.88%
05/17PHARMASGP : Another revenue record ? Q1 2022 revenues up 67% year-on-year
EQ
04/28PharmaSGP Holding SE Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/27PHARMASGP HOLDING SE : Notification and public disclosure of transactions by persons
EQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
05/17/2022 05/18/2022 05/19/2022 05/20/2022 05/23/2022 Date
24.4(c) 23.8(c) 23.3(c) 24.3(c) 25(c) Last
840 1 988 405 278 1 361 Volume
+1.24% -2.46% -2.10% +4.29% +2.88% Change
More quotes
Estimated financial data (e)
Sales 2022 80,5 M 86,0 M 86,0 M
Net income 2022 10,6 M 11,3 M 11,3 M
Net Debt 2022 54,8 M 58,5 M 58,5 M
P/E ratio 2022 27,6x
Yield 2022 1,79%
Sales 2023 86,7 M 92,6 M 92,6 M
Net income 2023 12,5 M 13,4 M 13,4 M
Net Debt 2023 40,2 M 42,9 M 42,9 M
P/E ratio 2023 23,4x
Yield 2023 2,00%
Capitalization 300 M 321 M 321 M
EV / Sales 2022 4,41x
EV / Sales 2023 3,92x
Nbr of Employees 66
Free-Float 22,2%
More Financials
Company
PharmaSGP Holding SE is a Germany based company, which operates as a pharmaceutical company. The Company produces and develops non-chemical and over-the-counter drugs and other healthcare products. 
Sector
Other Specialty Retailers
Calendar
-
More about the company
Ratings of PharmaSGP Holding SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about PHARMASGP HOLDING SE
05/17PHARMASGP : Another revenue record ? Q1 2022 revenues up 67% year-on-year
EQ
04/28PharmaSGP Holding SE Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/27PHARMASGP HOLDING SE : Notification and public disclosure of transactions by persons
EQ
04/25PHARMASGP HOLDING SE : Notification and public disclosure of transactions by persons
EQ
04/25PharmaSGP expects to see clear double-digit revenue and profit growth in 2022
EQ
04/25PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022
CI
04/04PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in..
EQ
04/04PharmaSGP Proposes Dividend for 2021
CI
03/15PharmaSGP achieves record results in 2021 - Adjusted EBITDA in Q4 up fivefold year-on-y..
EQ
02/17PharmaSGP achieves record revenues in 2021 and exceeds analysts' expectations
EQ
02/17PharmaSGP Announces Revenue Results for the Financial Year 2021
CI
2021PHARMASGP HOLDING SE : Notification and public disclosure of transactions by persons
EQ
2021PHARMASGP HOLDING SE : Notification and public disclosure of transactions by persons
EQ
2021PharmaSGP Holding SE Reports Earnings Results for the Nine Months Ended September 30, 2..
CI
2021PharmaSGP reporting 34% revenue growth and increased profitability in Q3 2021
EQ
More news
News in other languages on PHARMASGP HOLDING SE
05/17PHARMASGP : Erneuter Rekordumsatz - Erstes Quartal 2022 mit 67% Wachstum gegenüber Vorjahr
05/17PHARMASGP : Erneuter Rekordumsatz - Erstes Quartal 2022 mit 67% Wachstum gegenüber Vorjahr
04/28PharmaSGP Holding SE annonce ses résultats pour l'exercice complet clos le 31 décembre ..
04/27PHARMASGP HOLDING SE : Meldung und öffentliche Bekanntgabe der Geschäfte von Personen
04/27PharmaSGP Holding SE
More news
Chart PHARMASGP HOLDING SE
Duration : Period :
PharmaSGP Holding SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMASGP HOLDING SE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 24,30 €
Average target price 34,50 €
Spread / Average Target 42,0%
EPS Revisions
Managers and Directors
Natalie Weigand Chief Executive Officer
Michael Rudolf Chief Financial Officer
Clemens Fischer Chairman-Supervisory Board
Madlena Hohlefelder Vice Chairman-Supervisory Board
Axel Rebien Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
PHARMASGP HOLDING SE-1.62%308
ULTA BEAUTY, INC.-16.80%17 917
L BRANDS-44.56%9 227
E.L.F. BEAUTY, INC.-36.01%1 108
SA SA INTERNATIONAL HOLDINGS LIMITED-17.96%542
LYKO GROUP AB (PUBL)-44.67%319